What type of study is this?

September 10, 2025

Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results

Key Points

Safety data indicates that administering durvalumab with gemcitabine through a 30 min infusion is feasible for treatment.
Preliminary results demonstrate effective support for chemotherapy in patients with advanced biliary tract cancer, potentially streamlining care.
Conducted as a Phase 3b single-arm study, the focus was on the safety profile of the new infusion regimen.
These early findings highlight the need for further research to assess long-term outcomes and overall effectiveness.

Abstract

Background: The global, single-arm, Phase 3b TOURMALINE study (NCT05771480) assesses the safety and efficacy of D+G-based chemotherapy as first-line tx in aBTC. Optimising care by reducing infusion time may benefit patients and physicians. Preliminary safety data, including 30 min infusion time with D are reported.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Jack Chater

Do‐Youn Oh

Masafumi Ikeda

Journals

Zeitschrift für Gastroenterologie

Actions

Institutions

University of California, Irvine

Seoul National University

Sungkyunkwan University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Safety of 30 min infusion of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in first-line treatment (tx) of advanced biliary tract cancer (aBTC): TOURMALINE early results

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider